Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

General Information

Summary The purpose of this study is to evaluate the safety of cross sequential escalating doses of AST-OPC1 administered among 5 cohorts at a single time-point between 21 and 42 days post injury, inclusively, to subjects with subacute cervical spinal cord injuries (SCI).
Clinical trials phase Phases 1/2
Start date (estimated) 2015-03-01
End date (estimated) 2018-12-31
Clinical feature
Label Spinal cord injury

Administrative Information

NCT number NCT02302157
ICTRP weblink
Other study identifiers
Name AST-OPC1-01
Source weblink
Public contact
Public email
Sponsors Asterias Biotherapeutics, Inc


Source pluripotent stem cell lines
Which differentiated cell type is used
Label oligodendrocyte precursor cell
Description A progenitor cell of the central nervous system that can differentiate into oligodendrocytes or type-2 astrocytes. This cell originates from multiple structures within the developing brain including the medial ganglion eminence and the lateral ganglionic eminence. These cells migrate throughout the central nervous system and persist into adulthood where they play an important role in remyelination of injured neurons.; This cell type can be purified from optic nerves and other regions of the embryonic, postnatal and adult rat CNS and can be differentiated in vitro to oligodendrocytes and type-2 astrocytes. Some references use the terms 'oligodendrocyte precursor cell' and 'oligodendrocyte type-2 astrocyte (O-2A) progenitor' to refer to the same entity (e.g., PMID:10704434), while others describe an oligodendrocyte type-2 astrocyte (O-2A) progenitor cell as the precurosr to oligodendrocyte- and type-2 astrocyte- progenitor cells (e.g, ISBN:9780702028991).


Recruitment Status Completed
Estimated number of participants 25